细胞外信号调节激酶与胶原在肝纤维化过程中的表达及相关性

Effects of chelerythine on hepatic TGF-β1 and α-SMA expression in rats with hepatic fibrosis

AIM: To study the effects of chelerythine on TGF-β1 and α-SMA expression of CCl₄ -induced hepatic fibrosis in rats.

METHODS: Models of hepatic fibrosis were established by hypodermic injection of tetrachloride, in combination with the control of nutrition and the drinking of 100 mL/L alcohol to rats. According to histological sections, hepatic fibrosis in rats emerged at the end of the fourth week. Subsequently different doses of chelerythine were used of hepatic fibrosis in rats. In addition, normal control group, fibrotic model group, γ-interform group in experiment was arranged. At the end of the eighth week, all the rats were executed. Transforming growth factor-β1 (TGF-β1) and α-smooth muscle actin (α-SMA) in liver were examined with the immunohistochemistrical technique.

RESULTS: The expression of TGF-β1 and α-SMA in liver of rats in fibrotic model group induced by CCl₄ were ameliorated significantly compared with the model group (TGF-β1: 6.08 ± 2.35, 4.31 ± 2.10, 4.7 ± 1.70 vs 9.33 ± 3.08; α-SMA: 3.75 ± 1.76, 3.23 ± 1.42, 3.20 ± 1.17 vs 6.67 ± 2.29, all P < 0.01). The expression of TGF-β1 and α-SMA in liver was not obviously different between all chelerythine groups and γ-INF group (4.23 ± 2.24, 3.38 ± 1.39, both P > 0.05).

CONCLUSION: Chelerythine can decrease the expression of TGF-β1 as well as α-SMA CCl4 -induced hepatic fibrosis in rats.